Role of Plasminogen-Activator Inhibitor Type 1 in the Pathogenesis and Outcome of the Hemolytic Uremic Syndrome
Open Access
- 10 September 1992
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 327 (11) , 755-759
- https://doi.org/10.1056/nejm199209103271102
Abstract
Deposition of fibrin in glomeruli and renal failure are characteristic features of the hemolytic uremic syndrome. An inhibitor of glomerular fibrinolysis has been detected in plasma from children with this disorder. In this study, we define the inhibitor and show that its plasma level is correlated with the outcome of the disease.Keywords
This publication has 11 references indexed in Scilit:
- Plasminogen activator inhibitor (PAI‐1) in plasma and plateletsBritish Journal of Haematology, 1988
- Analysis of the plasminogen activator activity of the human glomerulusKidney International, 1988
- Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assayBlood, 1988
- Fibrinolytic Pathways and the EndotheliumSeminars in Thrombosis and Hemostasis, 1987
- Plasminogen activator inhibitorsBlood, 1987
- Report of the Second Task Force on Blood Pressure Control in Children—1987Pediatrics, 1987
- Peritoneal Permeability to Proteins in Diabetic and Non-Diabetic Continuous Ambulatory Peritoneal Dialysis PatientsNephron, 1986
- Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.Journal of Clinical Investigation, 1984
- Plasma inhibitor of glomerular fibrinolysis in the hemolytic-uremic syndromeThe American Journal of Medicine, 1982
- Synthesis of fibrinolytic activator and inhibitor by endothelial cellsProceedings of the National Academy of Sciences, 1977